Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of pharmaceutical drugs, including cell and gene therapy products and vaccines, is strengthening its scientific advisory board with the appointment of Bruce Kerwin.

Kerwin joins the scientific advisory board of Coriolis as a recognized industry expert in formulation and drug development with 30 years of experience leading project teams through multiple stages of development from pre-IND to commercialization. In previous positions at Umoja BioPharma, Just-Evotec Biologics, Amgen and Baxter Hemoglobin Therapeutics, Kerwin was responsible for research and strategies developing novel solutions to formulation problems such as high viscosity, high concentration, co-formulated proteins, and process development and formulation of viruses.

During his industry career he has published more than 60 peer-reviewed articles. As scientific advisor at Coriolis, Kerwin will bring his extensive industry and scientific expertise to the company and will serve as an additional point of contact for Coriolis’ customers and prospects in North America alongside the Coriolis business development team.

In close collaboration with Coriolis´ Science and Technology Unit, Kerwin will support the design and implementation of innovative formulation strategies and concepts for biopharmaceuticals and new entities, such as cell-based or virus-based products. In addition, Kerwin will represent the company at national and international scientific meetings.